Hassan: Congress' duty to fund FDA

Share this article:
Schering-Plough chairman and CEO Fred Hassan has set out an agenda for the newly elected US Congress when it convenes in January.

In remarks to the Cardiovascular Summit of more than 150 cardiovascular experts in advance of the American Heart Association's annual Scientific Sessions, Hassan said the lawmakers have a “moral obligation” to play for the long term. 

Hassan called on the new Congress to recognize that biopharmaceutical research is vital to the success of the US economy.

Hassan said the key to sustaining biopharmaceutical research is to preserve the strength and independence of FDA.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...